Results 111 to 120 of about 447,577 (315)

Desempenho dos marcadores EGFR, CK5, CK14, p63 e P-caderina para identificar o fenótipo basal do carcinoma de mama [PDF]

, 2007
Dissertação (mestrado) - Universidade Federal de Santa Catarina, Centro de Ciências da Saúde. Programa de Pós-Graduação em Ciências MédicasOs estudos dos perfis de expressão gênica dos carcinomas de mama identificaram um subtipo de tumor com pior ...
Vieira, Daniella Serafin Couto
core  

Risk Prediction Models for Recurrence After Curative Treatment of Early‐Stage or Locally Advanced Lung Cancer: A Systematic Review

Aging and Cancer, EarlyView.
This systematic review synthesizes prognostic models for survival and recurrence in resected non‐small cell lung cancer. While many models demonstrate moderate to good discrimination, few are externally validated and reporting quality is variable, limiting clinical applicability and highlighting the need for robust, transparent model development ...
Evangeline Samuel, S. Tissera, E. Paul, J. Zalcberg, R. G. Stirling   +4 more
wiley   +1 more source

Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (Egfr) Mutations with the Classical Mutation Pattern

, 2011
Background. Epidermal growth factor receptor (EGFR) mutations are usually detected in lung adenocarcinoma and are associated with a response to EGFR tyrosine kinase inhibitors (TKIs).
WU, SHANG-GIN;CHANG, YIH-LEONG;WU, JENN-YU;YANG, CHIH-HSIN;YU, CHONG-JEN;TSAI, MENG-FENG;SHIH, JIN-YUAN;YANG, PAN-CHYR, 吳尚俊;張逸良;巫震宇;楊志新;余忠仁;蔡孟峰;施金元;楊泮池   +1 more
core   +1 more source

Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma tau phosphorylated at threonine 217 (p‐tau217) measured with fully automated platforms has shown high accuracy for Alzheimer's disease (AD) diagnosis, but real‐world multicenter data remain limited. We aimed to validate the diagnostic performance of p‐tau217 for identifying AD pathology in a real‐world multicenter cohort ...
Miquel Massons, Nuria Guillen, Jordi Sarto, Neus Falgàs, Sergi Borrego‐Écija, Diana Esteller‐Gauxax, Magda Castellví, Adrià Tort‐Merino, Agnès Pérez‐Millan, Anna Antonell, Josep M. Augè Fradera, Gerard Piñol, Iolanda Riba, Anna Carnes‐Vendrell, Marta Cullell, Maria Teresa Osuna, Lorena Bajo, Teresa Romero, Eva Bonjoch, Joan Bello, Susana Fernández, Marta Balagué, Isabel Gómez‐Ruiz, Anuncia Boltes, Claustre Pont, Raquel Cuevas, Sara Carrillo, Laura Iglesias, Teresa Maria Casadevall Codina, Lorena Grau Guinea, Fernando Jose Espada, Raquel Sánchez‐Valle, Mircea Balasa, Albert Lladó   +33 more
wiley   +1 more source

Correlación entre la expresión del EGFR y el Ki-67 en astrocitomas difusamente infiltrantes en una serie de casos de la Fundación Centro Colombiano de Enfermedades Neurológicas y Epilepsia–Fire– de la ciudad de Cartagena de indias (Colombia)

Salud Uninorte, 2014
Objetivo: Identificar la relación entre expresión del EGFR y Ki-67 en tumores astrocíticos infiltrantes asociados con edad y sexo de los pacientes. Metodología: Se realizó un estudio descriptivo transversal.
Elsa Martínez-Muñoz, Martha Tuñón-Pitalúa, Zenén Carmona-Meza   +2 more
doaj  

Antitumor activity of a novel TLR9 agonist and cooperativity with targeted agents

, 2008
Novel modified Toll-like receptor 9 (TLR9) agonists, termed immune modulatory oligonucleotides (IMOs), exhibit antitumor activity and are currently investigated in cancer patients. Intriguingly, their mechanisms of action on tumor growth and angiogenesis
Garofalo, Sonia
core  

Spatial and Volumetric Characteristics of Glioblastoma: Associations With Clinical Presentation and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We aim to comprehensively analyze how regional tumor and edema characteristics are associated with clinical presentations and survival outcomes in a large cohort of glioblastoma patients. Methods Patients with IDH‐wildtype glioblastoma who received brain MRI from 2010 to 2023 were included.
Daniel J. Zhou, Marc Jaskir, Julian Gal, Yombe Fonkeu, Christos Davatzikos, MacLean P. Nasrallah, Jose Garcia, Rubo Xing, Stephen J. Bagley, Arati Desai, Richard E. Phillips, Steven Tobochnik, Colin A. Ellis, James J. Gugger, Nishant Sinha, Joel M. Stein, Kathryn A. Davis   +16 more
wiley   +1 more source

Molecular targets for metastasis-directed therapy in malignant tumors

Бюллетень сибирской медицины
Over the past two decades, targeted therapy has actively developed and, demonstrating impressive clinical results, has gained an increasingly important role in the treatment of cancer.
V. V. Bodenko, M. S. Larkina, A. A. Prach, E. V. Plotnikov, M. V. Belousov, V. I. Chernov   +5 more
doaj   +1 more source

Case report: EGFR fusion mutation combined with EGFR amplification responds to EGFR-TKI therapy

Frontiers in Oncology
Given their good antitumor effects, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR-sensitive mutations, including exon 19 deletions and exon 21 L858R mutations. EGFR fusion mutations and EGFR amplification are very rare in non-small cell lung cancer (NSCLC). We describe 2 patients with
Zhulin Wang, Zhulin Wang, Chunyao Huang, Wenbo Fan, Shaowu Sun, Kaiyuan Li, Xu Liu, Jiangtao Pu, Guoqing Zhang, Xiangnan Li   +9 more
openaire   +3 more sources

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma.

OncoTargets and therapy, 2020
With the rapid development of detection methods, next-generation sequencing (NGS) technology as a new technology, some novel epidermal growth factor receptor (EGFR) gene fusions comprising the EGFR linked to various fusion partners, most commonly RAD51, are detected in the non-small cell lung cancer (NSCLC). We described a case of an unreported kinesin
Xu, Hui, Shao, Chuan
openaire   +2 more sources